Spyre Therapeutics, Inc. (SYRE)

43.98 +0.53 (+1.22%) USD  |  NASDAQ  |  Feb 25, 14:57
More

Spyre Therapeutics EBITDA Estimates for Current Quarter

EBITDA Estimates for Current Quarter Chart

View EBITDA Estimates for Current Quarter for SYRE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View EBITDA Estimates for Current Quarter Chart
Start Trial

Historical Data

View Historical Data
Start Trial

EBITDA Estimates for Current Quarter Range, Past 5 Years

View EBITDA Estimates for Current Quarter Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

EBITDA Estimates for Current Quarter Benchmarks

View EBITDA Estimates for Current Quarter Benchmarks
Start Trial
PTC Therapeutics, Inc. Upgrade
Tandem Diabetes Care, Inc. Upgrade
ACADIA Pharmaceuticals, Inc. Upgrade
Alnylam Pharmaceuticals, Inc. Upgrade
Savara, Inc. --